WebMar 14, 2013 · Rasburicase (Fasturtec®) ist ein Enzym, welches Harnsäure in das wasserlöslichere Allantoin abbaut, welches besser renal ausgeschieden werden kann. Mit diesem Medikament lässt sich der Harnsäurespiegel im Blut schnell und sehr effizient senken. Die wichtigste Indikation für Rasburicase ist heute das Tumorlysesyndrom. Bei … WebFeb 21, 2024 · Fasturtec is given immediately before or during the start of chemotherapy. The recommended dose is 0.2 mg per kilogram body weight in both children and adults, given as a daily infusion for up to seven days. The duration of treatment is adjusted …
FASTURTEC Dosage & Drug Information CIMS India
WebJun 7, 2024 · Fasturtec is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae strain. The cDNA coding for rasburicase was cloned … WebPr fasturtec (rasburicase) - Sanofi Canada. EN. English Deutsch Français Español Português Italiano Român Nederlands Latina Dansk Svenska Norsk Magyar Bahasa Indonesia Türkçe Suomi Latvian Lithuanian česk ... fill blanks with cell above
FASTURTEC 1,5 mg/ml pdre/solv p sol diluer p perf - VIDAL
WebJul 8, 2011 · Rasburicase hingegen stellt ein Urikolytikum dar. Es handelt sich hierbei um eine rekombinante Uratoxidase, die Harnsäure in das wesentlich besser renal gängige … Web4.1 THERAPEUTIC INDICATIONS Rasburicase is indicated for the treatment and prophylaxis of acute hyperuricaemia, in patients with haematological malignancy at risk of a rapid tumour lysis. 4.2 DOSE AND METHOD OF ADMINISTRATION Rasburicase is to be used immediately prior to and during the initiation of chemotherapy WebAbstract. Intravenous rasburicase (Elitek, Fasturtec) is the first recombinant uricolytic agent. It is indicated for the management of anticancer therapy-induced hyperuricaemia in paediatric patients in the EU and US, and in adult patients in the EU. Rasburicase is effective and generally well tolerated in adult and paediatric patients with, or ... grounded eau potable